Welsh Statutory Instruments
NATIONAL HEALTH SERVICE, WALES
Made
21 March 2013
Laid before the National Assembly for Wales
22 March 2013
Coming into force
12 April 2013
The Welsh Ministers, in exercise of the powers conferred by sections 46(2), 203(9) and (10) of the National Health Service (Wales) Act 2006(1), make the following Regulations:
1.-(1) The title of these Regulations is the National Health Service (General Medical Services Contracts) (Prescription of Drugs Etc.) (Wales) (Amendment) Regulations 2013 and they come into force on 12 April 2013.
(2) These Regulations apply in relation to Wales.
2.-(1) The National Health Service (General Medical Services Contracts) (Prescription of Drugs Etc.) (Wales) Regulations 2004(2) are amended as follows.
(2) In Schedule 2 (drugs or medicines to be ordered only in certain circumstances)-
(a)in the entry for the drug Oseltamir (Tamiflu) for the entries in columns 2 and 3 respectively substitute-
(b)in the entry for the drugs for the treatment of erectile dysfunction, in column 2, after paragraph (f) insert-
"(g)a man who has been diagnosed as suffering severe distress resulting from erectile dysfunction where the assessment has been made by a specialist service or GP under arrangements made with a Local Health Board to provide such assessments".
(a)in the entry for the drug Zanamivir (Relenza) for the entries in columns 2 and 3 respectively substitute-
Mark Drakeford
Minister for Health and Social Services, one of the Welsh Ministers
21 March 2013
(This note is not part of the Regulations)
These Regulations amend the National Health Service (General Medical Services Contracts) (Prescription of Drugs Etc.) (Wales) Regulations 2004 ("the principal Regulations") which make provision as to the drugs, medicines or other substances that may be ordered for patients in the provision of medical services under a general medical services contract within the meaning of section 42 of the National Health Service (Wales) Act 2006.
Regulation 2 amends Schedule 2 to the principal Regulations (drugs or medicines to be ordered only in certain circumstances) to add further circumstances in which certain drugs may be ordered under such a contract. The drugs in question are Oseltamir (Tamiflu), Alprostadil (Caverject), (MUSE), (Viridal), Apomorphine Hydrochloride (Uprima), Moxisylyte Hydrochloride (Erecnos), Sildenafil (Viagra), Tadalafil (Cialis), Thymoxamine Hydrochloride (Erecnos), Vardenafil (Levitra), and the drug Zanamivir (Relenza).
The Welsh Ministers' Code of Practice on the carrying out of Regulatory Impact Assessments was considered in relation to these Regulations. As a result, it was not considered necessary to carry out a regulatory impact assessment as to the likely costs and benefits of complying with these Regulations.